Takeda Adds Medicinal Chemistry Heft To NYC Research Partnership
This article was originally published in The Pink Sheet Daily
Executive Summary
Joint research effort by three New York-based academic research organizations seeks to expedite translation of basic biomedical research into innovative therapies. Initial focus is on small molecules, but the plan is to branch out eventually into monoclonal antibodies and molecular imaging agents, as well.
You may also be interested in...
Bringing Urgency And Focus To Takeda: An Interview With Tachi Yamada
In a wide-ranging interview conducted at Elsevier’s PSA 2013 conference, Takeda’s R&D chief spoke of progress in building a global vaccine business, of the key late-stage assets that will carry the company into the next decade, and of business development priorities in the post-Nycomed era.
Deals of the Week: Is Astex Settling For An Underpriced Buyout?
A new life sciences hedge fund operated by two former associates of activist investor Carl Icahn is challenging Otsuka’s takeover of cancer drug developer Astex. Also, Johnson & Johnson’s London Innovation Center announced four alliances, Celgene took another option on one of its investments and Takeda teamed up with New York research institutions to form a new discovery institute.
Pharma Continues Its March To Academia, as Sanofi, UCB Strike Deals
In two very different collaborations, Sanofi teams up with Weill Cornell professor to screen for TB drug candidates, while UCB initiates its first project under a strategic research alliance with Harvard.